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Background: Asthma in the elderly is poorly understood and vitamin D deficiency and insufficiency are very
common in older individuals. We studied the role of vitamin D in elderly asthmatics.
Methods: Asthmatics subjects, age 65 and older, were followed every 4 weeks for 12 weeks in the late fall and
winter. During the study period they took 2,000 I.U. vitamin D3 daily. Serum 25-Hydroxyvitamin D and calcium were
measured at baseline and study end.
Results: Twenty nine percent of subjects were deficient and 50% insufficient in serum vitamin D at baseline. Serum
vitamin D increased from 24.3±9.2 ng/ml (60.7±23 nmol/L) to 34±7.1 ng/ml (84.9±17.7 nmol/L) at the end of the
study (p<0.001), whereas calcium was unchanged. We found no significant association between vitamin D and
subjects' demographics. Vitamin D was similar in men and women. There was no association between serum
vitamin D and inhaled steroid dose. Vitamin D was significantly lower in subjects with uncontrolled asthma (Asthma
Control Test, ACT≤19) compared to the ones with well controlled symptoms (p<0.05). In subjects with uncontrolled
asthma at baseline, ACT scores increased significantly at the end of the study (p<0.04), but not at 4 and 8 weeks.
Spirometric values remained unchanged throughout the study.
Conclusions: Elderly asthmatics very commonly have vitamin D deficiency or insufficiency. Serum vitamin D levels
were lower in subjects with uncontrolled asthma. In these subjects, vitamin D supplementation for 12 weeks led to
improved ACT scores. Larger, randomized, placebo controlled studies are required to further evaluate whether
vitamin D supplementation may improve asthma symptoms in this population.
Trial registration: ClinicalTrials.gov NCT01730976.
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Background
About 13% of the U.S. population is older than 65 years
and this percentage will nearly double by the year 2050
[1]. Approximately 7% of individuals 65 years old and
older have asthma [1]. However, little is known about
asthma in this group of patients as most studies have not
included elderly subjects. Elderly asthmatics are more
likely to be underdiagnosed, undertreated, and hospital-
ized when compared to younger asthmatics [1]. Asthma’s
pathophysiology is different in the elderly and there are
many challenges in the treatments of these patients [1].* Correspondence: michelecolumbo@msn.com
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unless otherwise stated.We have recently shown that measuring exhaled nitric
oxide in elderly asthmatics may be unwarranted [2].
Several studies have suggested that vitamin D deficiency
and insufficiency are extremely common, even in people
with abundant sun exposure [3,4]. The vitamin D receptor
is present in the bronchial smooth muscle [5] and lower
vitamin D levels may lead to bronchial smooth muscle
proliferation, cytokine release and airway remodeling
[5-8]. In addition, vitamin D has been shown to play a role
in immunomodulation by interacting with T lymphocytes,
dendritic cells, mast cells, monocytes and macrophages
[9]. Therefore, it is not surprising that vitamin D deficiency
has been associated with airway hyperresponsiveness, lower
pulmonary function, and worse asthma control [3,10].
Older age and vitamin D deficiency are predictors of
higher all cause mortality [11]. We are unaware of studiesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Subjects’ characteristics at baseline
Age (years, range) 72.6 ± 5.8, 65-84
Sex (F/M) 16/12
BMI 25 ± 3.2
Atopy 25/28
Duration of asthma (years) 34.3 ± 21.1
Rhinitis 25/28
Gastroesophageal reflux disease 7/28
Osteoporosis 2/28
Heart disease 2/28
Inhaled steroids (dose, range) 25/28(470 ± 341, 0-1200 mcg/day)
Long-acting bronchodilators 19/28
Leukotriene antagonist 13/28
ACT score 22.4 ± 3.2
Serum vitamin D (ng/ml) 24.3 ± 9.2
Serum calcium (mg/dl) 9.6 ± 0.3
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mentation in elderly asthmatics, a group particularly at
risk for vitamin D insufficiency and deficiency.
Therefore, we performed a pilot study in elderly asth-
matics investigating whether any association exists between
serum vitamin D levels and age, Body Mass Index (BMI),
and disease duration. We also studied whether serum
vitamin D levels vary in relationship to asthma drugs,
spirometric values and at different levels of asthma
control, measured by the ACT. Finally, we looked at the
effect of vitamin D3 supplementation (2,000 I.U./day)
for 12 weeks on ACT scores and spirometric measure-
ments. As sun exposure is the main source of vitamin D,
the results of studies of vitamin D and its supplementation
can be affected by seasonal fluctuations in sun exposure.
For that reason our study was performed in the late fall
and winter.
Methods
This study was performed in the period between
November 1, 2012 and March 18, 2013. Twenty-eight
subjects 65 years old and older with asthma (25 white,
3 African-American) followed in an Allergy and Immun-
ology practice in suburban Philadelphia were included
in the study. Current smokers or subjects with more
than 10 pack-years history of smoking were excluded.
Almost all study subjects were lifetime nonsmokers.
Subjects with hypercalcemia (≥10.5 mg/dl), with hyper-
vitaminosis D (≥100 ng/ml), those taking digoxin or
with liver disease were also excluded. None of the study
subjects had other comorbidities such as renal disease,
depression, or collagen vascular disease. Additional vitamin
D containing supplements were not allowed for at least
two weeks prior to the initial study visit and for the
duration of the study. This study was approved by the
Main Line Hospitals Institutional Review Board.
The presence of atopy was verified by allergy skin tests
for relevant environmental allergens. Spirometric values
were obtained according to the ATS/ERS guidelines by a
KoKo Spirometer (nSpire Health, Inc, Longmont, Color-
ado). 25-Hydroxy vitamin D and calcium were measured
in the serum of the study subjects at the Main Line Health
Laboratories, Bryn Mawr, PA. Subjects with serum vitamin
D levels of less than 20 ng/ml (49.9 nmol/L) were classi-
fied as deficient, whereas levels ranging between 20 and
29 ng/ml (49.9 and 72.4 nmol/L) were considered as vita-
min D insufficiency. Serum vitamin D and calcium levels
were measured at study entry and at the end of the study
(12 weeks later).
The inhaled steroids used by the study subjects were
fluticasone (15), budesonide (6), mometasone (3), and
beclomethasone (1). Steroid doses were expressed as
fluticasone-equivalent. The long-acting bronchodilators
were salmeterol (12) and formoterol (7). Montelukastwas the only leukotriene antagonist used by the study
subjects.
The study subjects were followed for 12 weeks with
evaluations including a brief history, physical exam,
collection of ACT scores and performance of a spirom-
etry at baseline and at 4, 8, and 12 weeks. The ACT is a
commonly used tool that allows patients to grade their
asthmatic symptoms. Patients report their asthmatic
symptoms during the previous four weeks on a scale
from 1 (severe) to 5 (no symptoms) by answering five
questions about their asthma. Values over 19 are consid-
ered as indicative of good asthma control.
Each study subject was instructed to take one softgel of
Vitamin D3 2,000 IU (Vitamin Shoppe, North Bergen, NJ)
daily every morning for 12 weeks. The study subjects were
asked to bring the bottle containing vitamin D3 softgels at
the three additional study visits for a visual inspection.
The bottles and the unused softgels were collected at the
end of the study and the remaining softgels counted and
their number recorded.
Data were analyzed by the two tailed, unpaired Student’s
t test and the Pearson correlation coefficient. Descriptive
variables were expressed as means and standard deviations.
Significance was accepted at alpha = .05 with no adjustment
for multiple comparisons.
Results
Table 1 shows the study subjects’ characteristics at base-
line. Most subjects were atopic (93%), on inhaled steroids
(89%), had well controlled asthma (79%) and coexistent
rhinitis (89%). Vitamin D deficiency and insufficiency were
very common. In particular, 29% of subjects were deficient
(<20 ng/ml) and 50% insufficient (20-29 ng/ml) in serum
vitamin D at baseline.
Table 3 Serum vitamin D at different inhaled steroids






I.C.S. >400 mcg/day 687 ± 248 - 22.8 ± 9.6
0.27
I.C.S. ≤400 mcg/day 134 ± 107 - 26.6 ± 8.5
ACT ≤19 - 17 ± 1.7 19 ± 5.6
0.045
ACT >19 - 23.9 ± 1.3 25.7 ± 9.6
I.C.S. = Inhaled corticosteroids.
Columbo et al. Allergy, Asthma & Clinical Immunology 2014, 10:48 Page 3 of 5
http://www.aacijournal.com/content/10/1/48We found no significant association between serum
vitamin D and age, BMI, and duration of asthma (Table 2).
Vitamin D was similar in men and women (24.4 ± 10.3 vs.
24.1 ± 8.1 ng/ml, respectively).
At baseline, serum vitamin D was similar in subjects
using higher doses of inhaled steroids (>400 mcg/day,
n = 17) when compared to the ones on lower doses
(Table 3). Inhaled steroid dose was not associated with
serum vitamin D (r = -0.2, p = 0.31). There was no
significant difference in serum vitamin D in subjects on
long-acting bronchodilators (26 ± 9.8 ng/ml, n = 19, vs.
20.7 ± 7.1 ng/ml in untreated subjects, n = 9, p = 0.12)
or on montelukast (25.4 ± 10.4 ng/ml, n = 13). Twenty
percent of study subjects had uncontrolled asthma
(ACT ≤ 19) at baseline (M= 1/F = 5, age 73.3 ± 5.5 years,
n = 6). In these subjects, serum vitamin D was significantly
lower than in subjects who were well controlled (Table 3).
In subjects with lower baseline FEV1% (<70% of the
predicted value, mean 57 ± 8.9%, n = 13), serum vitamin
D was essentially the same as in the rest of the study
subjects (23.9 ± 6.7 ng/ml). We found no association
between serum vitamin D and baseline FEV1% (r = 0.34,
p = 0.08), FEV1/FVC (r = 0.11, p = 0.58), or FEF25-75%
(r = -0.11, p = 0.58), although there was a trend for an
association with FEV1%.
Supplementation of vitamin D3 (2,000 I.U./day) for 12
weeks lead to a significant increase in its serum levels of
approximately 10 ng/ml (to 34 ± 7.1 ng/ml, p < 0.001).
Overall, FEV1% and ACT scores did not vary throughout
the study period (70.5 ± 15, p = 0.99, and 22.8 ± 2.9, p = 0.66
at 12 weeks, respectively). In subjects with uncontrolled
asthma (ACT = 17 ± 1.7), ACT scores similarly did not
change at 4 and 8 weeks (18 ± 0.7 and 18.5 ± 4.4,
respectively, p > 0.46), However, in these subjects ACT
scores increased significantly after 12 weeks of vitamin
D3 supplementation (20.2 ± 2.7, p = 0.039) (Figure 1). In
these subjects, the asthma treatment was essentially
unchanged (inhaled steroid dose at baseline = 620 ± 263
mcg/day vs. 718 ± 314 mcg/day at 12 weeks, p = 0.57) and
serum vitamin D increased to 32.3 ± 4.7 ng/ml (p = 0.001).
In the same subjects with uncontrolled asthma, and in
those with baseline FEV1 < 70%, FEV1% did not change for
the duration of the study (p = 0.79 and p = 0.88 at 12
weeks, respectively). FEV1/FVC and FEF25-75% similarly
remained unchanged throughout the study period (data
not shown).Table 2 Associations between subjects’ serum vitamin D
and demographics
Correlation coefficient (r) P value
Age -0.02 0.92
BMI -0.24 0.22
Duration of asthma 0.25 0.2As expected, vitamin D3 supplementation was well
tolerated and none of the study subjects complained of
adverse effects from this treatment during the study
period. Serum calcium levels remained the same at the
end of the study (9.55 ± 0.42 mg/dl). However, in two
study subjects, with baseline serum calcium of 10.2 mg/dl
and 9.6 mg/dl, these levels increased at 12 weeks to
10.7 mg/dl and 10.5 mg/dl, respectively.
Discussion
In the present study we investigated the role of vitamin
D in a group of elderly subjects with asthma. Similar to
our study, it has been recently reported that allergic
sensitization is very common in asthmatic patients older
than 55 years old [12].
In our study, 79% of the subjects had lower than
normal serum vitamin D at baseline. These results confirm
in elderly subjects that vitamin D deficiency and insuffi-
ciency are extremely common in patients with asthma and
respiratory disease [13,14]. Vitamin D deficiency is more
common with obesity, and serum vitamin D levels are in-
versely related to BMI [10]. We did not find an association
between serum vitamin D and BMI, age or duration of
asthma, and its values were similar in men and women.Figure 1 Effect of vitamin D supplementation on ACT scores in
subjects with uncontrolled asthma. Individual columns (blue, red,
green, and purple) represent ACT values obtained at baseline and at
4, 8, and 12 weeks, respectively for the six subjects.
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of our study subjects had a BMI of 30 or higher.
Serum vitamin D has been found to be inversely, al-
though weakly correlated with inhaled steroid dose in chil-
dren [13]. Our results failed to show such an association
and are in agreement with previous results in asthmatic
adults [13]. Serum vitamin D did not vary in subjects
treated with long-acting bronchodilators or montelukast.
In children, serum vitamin D was positively associated
with the ACT scores [15]. We found that in elderly
subjects with uncontrolled asthma (<19) serum vitamin
D was significantly lower than in the subjects whose
asthma was controlled. Our results are in agreement
with a recent study of adult asthmatics that showed that
serum vitamin D was lower in subjects with uncontrolled
symptoms [16]. We have very recently found that in
elderly subjects with uncontrolled symptoms of perennial
allergic rhinitis serum vitamin D is inversely related to
nasal symptoms (unpublished observations).
FEV1% values have been found positively, albeit weakly
associated with serum vitamin D in asthmatic children
and adults [15,17]. In our study, no significant association
was found between serum vitamin D and spirometric
values, and vitamin D was similar in subjects with lower
FEV1% (<70%). It is possible that a larger number of
observations would have produced a weak, yet significant
association with FEV1% similar to previous studies.
Vitamin D3 supplementation in asthmatic children
reduces the risk of recurrent respiratory infections and
asthma exacerbations [18]. A small study in mostly non-
white children with an average ACT score of 18 failed to
show an effect of one year vitamin D supplementation
(1,000 I.U./day) on ACT scores and FEV1% [19]. Similarly,
we did not find a variation of the spirometric values and
ACT scores after a 12 week vitamin D3 supplementation.
However, we did find a significant improvement of the
ACT scores at the end of the study in the subjects with
uncontrolled asthma (ACT < 19). These results may
have occurred because of a placebo effect or by chance.
However, such findings may encourage studies of vitamin
D in uncontrolled elderly asthmatics. A larger study of
vitamin D supplementation in adults with asthma with
serum vitamin D of less than 30 ng/ml was very recently
published [20]. In this study, vitamin D 4,000 I.U./day
for 28 weeks did not reduce treatment (inhaled steroid)
failure and exacerbations nor did it improve FEV1 and
asthma control. However, this study differed from ours
in that it involved a younger patient population (average
age 40 years old), in the obese range (average BMI 32),
almost 50% non-white, and enrolled subjects throughout
the different seasons [20]. Another very recent study of
adult asthmatics reported an association between vitamin
D sufficiency and decreased exacerbations and emergency
room visits over a five year period [21].Whereas expectedly vitamin D3 supplementation was
well tolerated, we found a mild elevation of the serum
calcium in two subjects after 12 weeks. This suggests
that in elderly subjects it would be reasonable to meas-
ure serum calcium before and after several months of
vitamin D supplementation.
Limitations of our study include the relatively small
number of subjects, almost exclusively caucasian with
well controlled asthma, and the lack of a placebo group.
However, the results of our study in elderly asthmatics
appear to confirm previous findings about the importance
of vitamin D in asthma and may encourage larger studies
in this patients group.
Conclusions
In summary, our pilot study suggests that vitamin D may
play a role in elderly asthmatics. Our results will require
confirmation in larger patient cohorts.
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